{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Benzodiazepine&page=12",
    "query": {
      "intervention": "Benzodiazepine",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 850,
    "total_pages": 85,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Benzodiazepine&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Benzodiazepine&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T09:46:17.101Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05542264",
      "title": "A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "SEP-363856",
          "type": "DRUG"
        },
        {
          "name": "Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 19,
      "start_date": "2022-11-15",
      "completion_date": "2024-02-12",
      "has_results": false,
      "last_update_posted_date": "2024-06-26",
      "last_synced_at": "2026-11-15T09:46:17.101Z",
      "location_count": 4,
      "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Dayton, Ohio + 1 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Dayton",
          "state": "Ohio"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05542264"
    },
    {
      "nct_id": "NCT07567781",
      "title": "A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ABBV-722",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Digoxin",
          "type": "DRUG"
        },
        {
          "name": "Pitavastatin",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2026-04-30",
      "completion_date": "2026-07-21",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-11-15T09:46:17.101Z",
      "location_count": 1,
      "location_summary": "Grayslake, Illinois",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07567781"
    },
    {
      "nct_id": "NCT06632990",
      "title": "A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug Drug Interaction (DDI)"
      ],
      "interventions": [
        {
          "name": "BMS-984923",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Caffeine",
          "type": "DRUG"
        },
        {
          "name": "dextromethorphan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allyx Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 36,
      "start_date": "2024-11-04",
      "completion_date": "2025-10-15",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-11-15T09:46:17.101Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06632990"
    },
    {
      "nct_id": "NCT04958226",
      "title": "A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumour"
      ],
      "interventions": [
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 21,
      "start_date": "2021-10-15",
      "completion_date": "2023-02-15",
      "has_results": false,
      "last_update_posted_date": "2024-01-25",
      "last_synced_at": "2026-11-15T09:46:17.101Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Durham, North Carolina • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04958226"
    },
    {
      "nct_id": "NCT02113813",
      "title": "A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small-Cell Lung Cancer (NSCLC)",
        "Epidermal Growth Factor Receptor Mutations"
      ],
      "interventions": [
        {
          "name": "naquotinib",
          "type": "DRUG"
        },
        {
          "name": "midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2014-04-09",
      "completion_date": "2019-02-11",
      "has_results": false,
      "last_update_posted_date": "2024-11-14",
      "last_synced_at": "2026-11-15T09:46:17.101Z",
      "location_count": 12,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 7 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02113813"
    },
    {
      "nct_id": "NCT00363376",
      "title": "A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Weight Gain"
      ],
      "interventions": [
        {
          "name": "Zonisamide",
          "type": "DRUG"
        },
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Sugar Pill (placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lindner Center of HOPE",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2008-01",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2012-04-13",
      "last_synced_at": "2026-11-15T09:46:17.101Z",
      "location_count": 1,
      "location_summary": "Mason, Ohio",
      "locations": [
        {
          "city": "Mason",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00363376"
    },
    {
      "nct_id": "NCT01069822",
      "title": "A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "AZD6765",
          "type": "DRUG"
        },
        {
          "name": "midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 46,
      "start_date": "2010-02",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2014-10-13",
      "last_synced_at": "2026-11-15T09:46:17.101Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01069822"
    },
    {
      "nct_id": "NCT00248729",
      "title": "Effectiveness and Safety Study of Etomidate Versus Midazolam to Help Place a Breathing Tube Outside of the Hospital.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Failure"
      ],
      "interventions": [
        {
          "name": "Etomidate (20mg) or Midazolam (7mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Luke's Hospital, Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-10",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2025-05-14",
      "last_synced_at": "2026-11-15T09:46:17.101Z",
      "location_count": 1,
      "location_summary": "Bethlehem, Pennsylvania",
      "locations": [
        {
          "city": "Bethlehem",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00248729"
    },
    {
      "nct_id": "NCT00678457",
      "title": "Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Dependence"
      ],
      "interventions": [
        {
          "name": "Ondansetron",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2007-01",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2009-01-30",
      "last_synced_at": "2026-11-15T09:46:17.101Z",
      "location_count": 2,
      "location_summary": "Charlottesville, Virginia • Richmond, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00678457"
    },
    {
      "nct_id": "NCT00208819",
      "title": "A Comparison of Two Standard Therapies in the Management of Dementia With Agitation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Senile Dementia, Alzheimer Type",
        "Dementia, Alzheimer Type",
        "Alzheimer Disease",
        "Dementia"
      ],
      "interventions": [
        {
          "name": "risperidone",
          "type": "DRUG"
        },
        {
          "name": "quetiapine",
          "type": "DRUG"
        },
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "divalproex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2003-09",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2013-11-13",
      "last_synced_at": "2026-11-15T09:46:17.101Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00208819"
    }
  ]
}